Qingdao Vland Biotech INC
SSE:603739

Watchlist Manager
Qingdao Vland Biotech INC Logo
Qingdao Vland Biotech INC
SSE:603739
Watchlist
Price: 15.59 CNY -0.13% Market Closed
Market Cap: 3.9B CNY

Relative Value

The Relative Value of one Qingdao Vland Biotech INC stock under the Base Case scenario is 28.87 CNY. Compared to the current market price of 15.59 CNY, Qingdao Vland Biotech INC is Undervalued by 46%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
28.87 CNY
Undervaluation 46%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Qingdao Vland Biotech INC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Qingdao Vland Biotech INC
SSE:603739
3.9B CNY 2.8 47.2 29.8 29.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 111 463.2 -162 126.7 -169 586.9 -167 651.7
US
Abbvie Inc
NYSE:ABBV
379B USD 6.4 161.4 15.7 22.3
US
Amgen Inc
NASDAQ:AMGN
177.9B USD 4.9 25.4 18.3 18.3
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD 5.3 19.1 12.8 12.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD 9.6 30.5 22.3 23.3
US
Epizyme Inc
F:EPE
94.1B EUR 2 065.3 -527 -666.2 -648.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD 5.4 16.9 16 18.2
AU
CSL Ltd
ASX:CSL
85.5B AUD 3.7 19.1 8.6 10.7
NL
argenx SE
XBRU:ARGX
41.7B EUR 13.5 31.7 62.4 64.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD 14.7 1 086 146.3 177.5
P/E Multiple
Earnings Growth PEG
CN
Qingdao Vland Biotech INC
SSE:603739
Average P/E: 159.7
47.2
25%
1.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 126.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
161.4
89%
1.8
US
Amgen Inc
NASDAQ:AMGN
25.4
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.1
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
10%
1.7
AU
CSL Ltd
ASX:CSL
19.1
11%
1.7
NL
argenx SE
XBRU:ARGX
31.7
40%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 086
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Qingdao Vland Biotech INC
SSE:603739
Average EV/EBITDA: 36.9
29.8
49%
0.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -169 586.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.7
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
18.3
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -666.2 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16
11%
1.5
AU
CSL Ltd
ASX:CSL
8.6
8%
1.1
NL
argenx SE
XBRU:ARGX
62.4
810%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
146.3
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Qingdao Vland Biotech INC
SSE:603739
Average EV/EBIT: 41.9
29.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -167 651.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.3
30%
0.7
US
Amgen Inc
NASDAQ:AMGN
18.3
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.8
12%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -648.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.2
13%
1.4
AU
CSL Ltd
ASX:CSL
10.7
11%
1
NL
argenx SE
XBRU:ARGX
64.1
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
177.5
N/A N/A